Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) to Present Company Overview at Upcoming Conferences

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, MA--(Marketwired - July 30, 2013) - Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in August. Chris Garabedian, Sarepta’s president and chief executive officer, will be the presenter.

  • Wedbush Securities Life Sciences Management Access Conference in New York, NY on Tuesday, August 13, 2013 at 8:35 a.m. Eastern Time.
  • Canaccord Annual Growth Conference in Boston, MA on Thursday, August 15, 2013 at 8:30 a.m. Eastern Time.

The presentations will be webcast live on the investor relations section of Sarepta Therapeutics’ website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.


Sarepta Investor Contact:
Erin Cox
857.242.3714
Email Contact

Sarepta Media Contact:
Jim Baker
857.242.3710
Email Contact

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC